Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:35:56.530Z.
Calculation as of: 2026-10-06T21:35:56.530Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d16669f7a2c0e1646e6313a61118319ccaec2b3022f40527d46d929c834448
PE RATIO
N/A
Market Cap
$235.08M
PE Ratio
22.51
TTM Avg
18.71
3Y Avg
16.51
5Y Avg
18.62
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $236.82M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $237.57M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | N/A | 10.01 | 8.82 | 11.38 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | N/A | N/A | N/A | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 22.51 | 18.71 | 16.51 | 18.62 |
| High Tide Inc. (HITI)vs › | $239.01M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $239.02M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $241.34M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 2.91 | 4.27 | 4.27 | 3.78 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$6.29
Forward EPS (Est.)
$-2.43
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
